Shots:

• The P-III CheckMate-548 (NCT02667587) study involves assesing of Opdivo + SoC (temozolomide & radiation therapy) vs SoC monothx in patients newly diagnosed GBM that is MGMT-methylated- with its 1EP as PFS per blinded independent central review (BICR) & OS and 2EPs as investigator assess PFS & OS rate ~2yrs.
• The study resulted in unmet one of its 1EP showing no improvement in PFS for patients
• Opdivo is a PD-1 immune checkpoint inhibitor targeted to harness body’s own immune system further restoring anti-immune response and is approved in 65+ countries including the US- EU- Japan and China

Click here to read full press release/ article

Ref: Bristol-Myers Squibb | Image: BMS